Lotrel T0.5%+0.3%

Lotrel T ophthalmic suspension is indicated for steroid-responsive inflammatoryocular conditions for which a corticosteroid is indicated and where a superficial bacterialocular infection or a risk of bacterial ocular infection exists.

• Established/approved use: Treatment of inflammatory conditions of the palpebraland bulbar conjunctiva, cornea, and anterior segment of the eye (such as post-operativeinflammation following ocular surgery, and blepharoconjunctivitis) when the inherent risk ofcorticosteroid use is accepted to obtain a beneficial anti-inflammatory effect and a bacterialinfection or risk of bacterial infection is present.
• Typical clinical scenarios: Post-operative ocular inflammation (e.g. aftercataract or other intraocular surgery) with risk of bacterial superinfection; blepharitis/blepharoconjunctivitis with a bacterial component.

Lotrel T is not indicated for uncomplicated bacterial conjunctivitis without an inflammatorycomponent requiring a corticosteroid, and it should not be used for undiagnosed red eye withoutprior ophthalmologic evaluation.

Each mL of Loteprednol Etabonate + Tobramycin ophthalmic suspension typically contains loteprednol etabonate 0.5% (a topicalcorticosteroid) combined with tobramycin 0.3% (an aminoglycoside antibiotic), along withinactive/suspending ingredients. Strength and exact formulation may vary slightly by manufacturer;always check the product label of the dispensed brand.

Lotrel T is a fixed-dose combination ophthalmic (eye) suspension that pairs a corticosteroid(loteprednol etabonate) with an aminoglycoside antibiotic (tobramycin). It is formulated as asterile topical ophthalmic suspension intended to reduce ocular inflammation while covering for,or preventing, an accompanying bacterial infection.

Loteprednol etabonate is a "soft" corticosteroid designed to be metabolized rapidly to inactivemetabolites, which is intended to reduce the risk of intraocular pressure elevation compared withsome older ophthalmic steroids, although this risk is not eliminated. Tobramycin is a bactericidalaminoglycoside active against many Gram-negative and some Gram-positive ocular pathogens.

Lotrel T belongs to the therapeutic class of ophthalmic corticosteroid–antibioticcombinations, combining a corticosteroid (loteprednol etabonate) with an aminoglycosideantibiotic (tobramycin) for topical ocular use.

Mechanism of Action

Loteprednol Etabonate + Tobramycin combines two active components with complementary actions:

• Loteprednol etabonate is a corticosteroid that suppresses the inflammatoryresponse to mechanical, chemical, or immunological agents by inhibiting edema, fibrin deposition,capillary dilation, leukocyte migration, and capillary proliferation associated with ocularinflammation. It is an ester-based ("soft") steroid that undergoes rapid conversion to an inactivemetabolite after exerting its anti-inflammatory effect, which is designed to limit systemic andocular corticosteroid exposure.
• Tobramycin is an aminoglycoside antibiotic that acts by irreversibly binding tothe bacterial 30S ribosomal subunit, inhibiting bacterial protein synthesis and producing abactericidal effect against susceptible Gram-negative organisms (including Pseudomonasaeruginosa) and several Gram-positive organisms (including Staphylococcus aureus).

Pharmacokinetics

Following topical ophthalmic administration of Loteprednol Etabonate + Tobramycin, systemic absorption of both components isgenerally low. Loteprednol etabonate is largely metabolized to inactive metabolites; tobramycinophthalmic use results in minimal systemic absorption, though it can be higher with cornealepithelial defects or prolonged/frequent dosing.

• Shake the bottle well before each use.
• Wash hands before instilling the drops.
• Tilt the head back, pull down the lower eyelid to form a small pocket, and instill theprescribed number of drops without letting the dropper tip touch the eye, eyelid, or any othersurface (to avoid contamination).
• Close the eye gently for 1–2 minutes after instillation; applying light pressure at the innercorner of the eye (nasolacrimal occlusion) may reduce systemic absorption.
• If using other topical ophthalmic medicines, space administration at least 5–10 minutes apartfrom Lotrel T.
• Do not touch the dropper tip to any surface; replace the cap after use.

Because Lotrel T is applied topically to the eye, systemic absorption is low and clinicallysignificant systemic drug interactions are uncommon. Established interaction considerationsinclude:

• Other topical ophthalmic products: Concurrent use of other topical eyemedications may dilute or wash out Lotrel T; separate administration by several minutes.
• Other corticosteroid-containing ophthalmic products: Concomitant use withother topical ocular corticosteroids is generally unnecessary and may increase the risk ofsteroid-related adverse effects; avoid duplicate steroid therapy unless directed by a physician.
• Systemic aminoglycosides: Clinically significant interaction with systemicototoxic/nephrotoxic drugs is not expected at ophthalmic doses of Lotrel T, but physicians should beinformed of all concurrent medications.

Always inform your physician or pharmacist of all other medicines, including other eye drops,being used before starting Lotrel T.

Adverse effects reported with Lotrel T relate to both the corticosteroid and antibiotic components:

• Common: Ocular discomfort/stinging or burning on instillation, blurred visionimmediately after application, eye itching or redness.
• Corticosteroid-related (with prolonged use): Elevated intraocular pressure/glaucoma, posterior subcapsular cataract formation, delayed wound healing, secondary ocularinfection (fungal or viral overgrowth due to suppression of the host immune response — seeContraindications for pre-existing viral/fungal disease), and rarely, globe perforation inconditions that cause corneal or scleral thinning.
• Antibiotic-related: Local hypersensitivity or allergic reactions; rarely,overgrowth of non-susceptible organisms with prolonged use.

Patients should notify their physician promptly if vision changes, eye pain, or persistentredness/irritation develop.

Pregnancy: There are no adequate and well-controlled studies of Lotrel T inpregnant women. As with other topical ophthalmic corticosteroid-antibiotic combinations, Lotrel Tshould be used during pregnancy only if the potential benefit justifies the potential risk to thefetus, and only under medical supervision.

Lactation: It is not known whether topical ophthalmic administration of Lotrel Tcould result in sufficient systemic absorption to be detected in human milk. Caution should beexercised, and Lotrel T should be used during breastfeeding only on a physician's advice, weighing thebenefit to the mother against any potential risk to the nursing infant.

• Intraocular pressure (IOP): Prolonged use of Lotrel T can result in elevated IOPand/or glaucoma, with possible damage to the optic nerve and defects in visual acuity and fields.If Lotrel T is used for 10 days or longer, IOP should be routinely monitored by an ophthalmologist.
• Cataract: Prolonged corticosteroid use may result in posterior subcapsularcataract formation.
• Delayed healing and secondary infection: Corticosteroids may suppress thehost immune response, increasing the hazard of secondary ocular infection (bacterial, fungal, orviral) and delaying wound healing; use with caution after cataract or other ocular surgery.
• Viral, fungal, and mycobacterial eye disease: Use of steroids may prolong thecourse and exacerbate the severity of many viral eye infections (including herpes simplex); Lotrel Tis contraindicated in these settings (see Contraindications).
• Undiagnosed red eye: Lotrel T should not be used for undiagnosed "red eye" withoutprior ophthalmologic evaluation, as corticosteroid use can mask or worsen an underlying infection.
• Hypersensitivity to aminoglycosides: Patients who develop sensitization fromtobramycin may show cross-sensitivity to other aminoglycoside antibiotics.
• Not for injection: For topical ophthalmic use only.
• Duration of use: Use Lotrel T strictly for the duration prescribed by thephysician; do not use for longer than directed. This medicine should be taken exactly asprescribed by your physician; do not stop, extend, skip doses, or share this medicine with otherswithout medical advice.
• Contact lenses: Avoid wearing contact lenses during treatment unless advisedotherwise by the prescriber, as the product may contain preservatives that can be absorbed by softlenses.

Topical ophthalmic overdose of Lotrel T is unlikely to cause acute systemic toxicity, but excessiveor prolonged use increases the risk of local adverse effects (elevated intraocular pressure,cataract, secondary infection — see Precautions and Warnings). If Lotrel T is accidentally swallowed,or if excessive instillation occurs, or if severe irritation, vision changes, or an allergicreaction develops, seek immediate medical attention or contact a poison control center/emergencyservices. Do not attempt unsupervised home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Shake the suspension well before each use. Keep the bottle tightly closed and out of reach of children. Discard any unused portion after the period recommended on the label once opened.

Pediatric Use

Safety and effectiveness of Lotrel T in pediatric patients below 2 years of age have not beenestablished. Use in children should be under close ophthalmologic supervision, with dosing andduration determined by the treating physician.

Elderly (Geriatric) Use

No overall differences in safety or effectiveness have been established between elderly andyounger adult patients; standard adult dosing generally applies, with appropriate monitoring.

Renal/Hepatic Impairment

Because systemic absorption of Lotrel T following ophthalmic administration is low, specific renalor hepatic dose adjustments are not well established and are generally not required; use withroutine caution in patients with significant hepatic or renal impairment.

The duration of treatment with Lotrel T should be determined by the prescribing physician based onthe severity of inflammation and clinical response, and is typically limited to the shortesteffective course. Treatment beyond the prescribed duration is not recommended withoutre-evaluation, and use of Lotrel T for 10 days or longer requires monitoring of intraocular pressureby an ophthalmologist.

Ophthalmic corticosteroid (loteprednol etabonate) combined with an aminoglycoside antibiotic (tobramycin); classified as an ophthalmic anti-inflammatory/anti-infective combination.

Loteprednol Etabonate + Tobramycin works through two complementary mechanisms: loteprednol etabonate, a corticosteroid,suppresses ocular inflammation by inhibiting inflammatory mediator release, capillary dilation,leukocyte migration, and fibrin deposition, while tobramycin, an aminoglycoside antibiotic, bindsirreversibly to the bacterial 30S ribosomal subunit to inhibit protein synthesis, producing abactericidal effect against susceptible ocular pathogens. Together, these actions reduceinflammation while treating or preventing an accompanying bacterial infection.

C

Lotrel T may be used in children under the direction and supervision of an ophthalmologist orphysician, but safety and effectiveness in pediatric patients below 2 years of age have not beenestablished. Because prolonged corticosteroid use carries a risk of elevated intraocular pressureand other steroid-related effects, pediatric use should be closely monitored, and treatmentlimited to the shortest effective duration prescribed by the physician.